Sanuwave Health (NASDAQ:SNWV) Trading Down 11% – What’s Next?

Sanuwave Health Inc. (NASDAQ:SNWV)’s share price dropped 11% on Thursday . The company traded as low as $7.53 and last traded at $7.63. Approximately 201,905 shares were traded during trading, an increase of 20% from the average session volume of 168,855 shares. The stock had previously closed at $8.57.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SNWV shares. Roth Mkm reaffirmed a “buy” rating and issued a $47.00 price target (down from $53.00) on shares of Sanuwave Health in a research report on Monday, March 30th. Wall Street Zen downgraded Sanuwave Health from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings upgraded Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, March 27th. Finally, Zacks Research cut Sanuwave Health from a “hold” rating to a “strong sell” rating in a research report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Sanuwave Health Trading Down 11.0%

The firm has a market cap of $65.62 million, a P/E ratio of 23.12 and a beta of 1.34. The company’s 50 day moving average is $15.45 and its two-hundred day moving average is $21.73. The company has a debt-to-equity ratio of 8.15, a current ratio of 1.31 and a quick ratio of 0.99.

Sanuwave Health (NASDAQ:SNWV) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). Sanuwave Health had a net margin of 35.96% and a negative return on equity of 450.56%. The firm had revenue of $9.62 million for the quarter, compared to the consensus estimate of $9.60 million.

Institutional Trading of Sanuwave Health

Several institutional investors have recently modified their holdings of SNWV. Goldman Sachs Group Inc. bought a new stake in shares of Sanuwave Health during the first quarter valued at approximately $337,000. Geode Capital Management LLC bought a new position in Sanuwave Health in the second quarter worth $5,184,000. JPMorgan Chase & Co. bought a new position in Sanuwave Health in the second quarter worth $109,000. Legal & General Group Plc acquired a new stake in Sanuwave Health during the second quarter worth $26,000. Finally, Rhumbline Advisers acquired a new stake in Sanuwave Health during the second quarter worth $211,000. Institutional investors and hedge funds own 42.53% of the company’s stock.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.